146 related articles for article (PubMed ID: 8013984)
21. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
22. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
23. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
24. Troubleshooting the collect concentration monitor alarm in therapeutic thrombocytapheresis.
Linn N; Bryan R; Ross M; Pereyra L; Lin D
J Clin Apher; 2018 Feb; 33(1):95-96. PubMed ID: 28560803
[No Abstract] [Full Text] [Related]
25. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
26. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
27. [Chronic myeloproliferative diseases. New knowledge about well known diseases].
Aulitzky WE; Griesshammer M; Heimpel H; Huhn D
Dtsch Med Wochenschr; 1996 May; 121(18):600-4. PubMed ID: 8625788
[No Abstract] [Full Text] [Related]
28. Characteristic changes in platelet-large cell ratio, lactate dehydrogenase and C-reactive protein in thrombocytosis-related diseases.
Kabutomori O; Kanakura Y; Iwatani Y
Acta Haematol; 2007; 118(2):84-7. PubMed ID: 17622783
[TBL] [Abstract][Full Text] [Related]
29. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
30. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
31. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
32. The role of blood component removal in essential and reactive thrombocytosis.
Greist A
Ther Apher; 2002 Feb; 6(1):36-44. PubMed ID: 11886575
[TBL] [Abstract][Full Text] [Related]
33. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
34. Platelet apheresis for digital gangrene due to thrombocytosis in chronic myeloid leukaemia.
Win N; Mitchell DC
Clin Lab Haematol; 2001 Feb; 23(1):65-6. PubMed ID: 11422234
[TBL] [Abstract][Full Text] [Related]
35. Platelet apheresis for extreme thrombocytosis in an 11-year-old girl with CML.
McCarthy LJ; Graves VL; Eigen H; McGuire WA
Transfus Med; 1991 Sep; 1(3):187-9. PubMed ID: 9259847
[TBL] [Abstract][Full Text] [Related]
36. [Therapeutic cytapheresis].
Wiebecke D; Gunzer U; Ullrich H; Kadar J
Beitr Infusionsther; 1991; 28():226-32. PubMed ID: 1725627
[TBL] [Abstract][Full Text] [Related]
37. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
Skotnicki AB; Wolska-Smoleń T
Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic plateletpheresis in thombocythemia.
Panlilio AL; Reiss RF
Transfusion; 1979; 19(2):147-52. PubMed ID: 432925
[TBL] [Abstract][Full Text] [Related]
39. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
40. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]